Necitumumab is an intravenously administered recombinant monoclonal IgG1 antibody used in the treatment of non-small cell lung cancer (NSCLC) as an EGFR antagonist.
It functions by binding to epidermal growth factor receptor (EGFR) and prevents binding of its ligands, a process that is involved in cell proliferation, metastasis, angiogenesis, and malignant progression.
Binding of necitumumab to EGFR induces receptor internalization and degradation, thereby preventing further activation of EGFR which is beneficial in NSCLC as many patients have increased protein expression of EGFR.
Necitumumab is approved for use in combination with cisplatin and gemcitabine as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC).
Applications:Suitable for use in ELISA and SDS-PAGE.
Other applications not tested.
Recommended Dilution:Optimal dilutions to be determined by the researcher.
Storage and Stability:May be stored at 4℃ for short-term only.
Aliquot to avoid repeated freezing and thawing.
Store at -20℃.
Aliquots are stable for 12 months after receipt.
For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
仕様
Size：100ug
抗体種類：Mab
宿主：human
Grade：Highly Purified
Purity：≥95%
Form：Supplied as a liquid in PBS, pH 7.5.
Specificity：Recognizes Necitumumab (EGFR/ERBB1 ).
Isotype：IgG1,k
Calc Applications Abbrev：E
Immunogen：Recombinant protein corresponding to EGFR/ERBB1 [Homo sapiens], expressed in CHO cells.
